Analysts Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $11.60

Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have been given a consensus rating of "Buy" by the eight ratings firms that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.60.

Several equities research analysts recently issued reports on IMUX shares. D. Boral Capital reiterated a "buy" rating and set a $10.00 price target on shares of Immunic in a report on Thursday, June 5th. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Immunic in a report on Thursday, May 1st. William Blair reiterated an "outperform" rating on shares of Immunic in a report on Friday, May 16th. Wall Street Zen cut Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. Finally, B. Riley reissued a "buy" rating and issued a $5.00 price objective (down previously from $6.00) on shares of Immunic in a research report on Friday, May 23rd.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Invesco Ltd. purchased a new position in shares of Immunic during the 4th quarter valued at $37,000. Barclays PLC purchased a new position in shares of Immunic during the 4th quarter valued at $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after buying an additional 96,894 shares during the last quarter. Bridgeway Capital Management LLC lifted its position in shares of Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after buying an additional 22,200 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after buying an additional 152,726 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company's stock.

Immunic Trading Down 4.6%

Immunic stock traded down $0.04 during trading on Wednesday, hitting $0.80. 960,155 shares of the company were exchanged, compared to its average volume of 886,213. The business's 50 day moving average is $0.95 and its 200 day moving average is $1.04. Immunic has a 52 week low of $0.56 and a 52 week high of $2.11. The company has a market capitalization of $77.12 million, a P/E ratio of -0.65 and a beta of 1.48.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.25). Equities analysts expect that Immunic will post -0.94 EPS for the current year.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.